ATAlberto Tommasini

Alberto Tommasini

*This is an algorithmically generated author record based on publicly available information.

Alberto Tommasini has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 16 April 2015
      • Vol. 33  (3) , 437-42

    Different presentations of mevalonate kinase deficiency: a case series.

    by Carlo De Pieri, Andrea Taddio, Antonella Insalaco, Egidio Barbi, Loredana Lepore, Alessandro Ventura, Alberto Tommasini

    We aimed to raise awareness among paediatricians and physicians about this often misunderstood condition. We discussed the clinical profiles associated with late or wrong diagnosis of mevalonate kinase deficency (MKD) in a single centre case series. We analysed the most common challenges and pitfalls that a clinician might face during the diagnostic process. Five main clinical profiles were characterised. We propose a new perspective on MKD, suggesting that the presentation of this disease can vary from patient to patient.


  • AMANTADINE IN CHRONIC GRANULOMATOUS DISEASE

    by Marilena Granzotto, Valentina Leone, Loredana Lepore, Marlenka Zerial, Alberto Tommasini, Roberta Ciambra, Francesca Gombac, Alessandro Ventura

    Chronic granulomatous disease (CGD) is a rare genetically determined immunodeficiency. Neutrophils from CGD patients show a defective killing of phagocytosed fungi and bacteria, due not only to an impairment in oxidative burst, but also to absence of normal pH value within phagocytic vacuole following phagocytosis. Because a weak base such as amantadine could potentially reverse these pH abnormalities, the authors used this drug to treat 2 CGD patients. They observed modifications of both phagosomal pH and killing activity on their neutrophils compared to those of healthy controls. Since the drug has been employed, the patients have not developed new infections, suggesting a role of amantadine as a part of CGD prophylactic regimen. These results suggest the opportunity of testing the drug in larger studies.


  • Open Access

    Anti-Transglutaminase Antibodies and Age

    by Valentina Baldas, Tarcisio Not, Alberto Tommasini, Filippo Ansaldi, Sergio Demarini, Daniele Sblattero, Roberto Marzari, Lucio Torelli, Alberto Burlina, Claudio Tiribelli, et al.